Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
10.87%
↑ 108% above average
Average (39q)
5.22%
Historical baseline
Range
High:42.05%
Low:-25.83%
CAGR
-1.6%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 10.87% |
| Q2 2025 | 22.06% |
| Q1 2025 | -11.68% |
| Q4 2024 | 10.79% |
| Q3 2024 | -7.89% |
| Q2 2024 | 12.70% |
| Q1 2024 | -4.10% |
| Q4 2023 | 7.49% |
| Q3 2023 | 1.87% |
| Q2 2023 | 7.79% |
| Q1 2023 | -12.01% |
| Q4 2022 | 6.79% |
| Q3 2022 | 19.28% |
| Q2 2022 | 21.08% |
| Q1 2022 | -25.83% |
| Q4 2021 | 17.72% |
| Q3 2021 | 6.54% |
| Q2 2021 | -1.76% |
| Q1 2021 | 10.35% |
| Q4 2020 | 4.13% |
| Q3 2020 | 4.38% |
| Q2 2020 | -8.60% |
| Q1 2020 | -15.76% |
| Q4 2019 | 25.19% |
| Q3 2019 | -1.89% |
| Q2 2019 | 26.92% |
| Q1 2019 | -1.46% |
| Q4 2018 | -6.37% |
| Q3 2018 | 1.72% |
| Q2 2018 | 42.05% |
| Q1 2018 | -17.76% |
| Q4 2017 | 23.64% |
| Q3 2017 | 5.10% |
| Q2 2017 | 4.19% |
| Q1 2017 | -17.17% |
| Q4 2016 | 7.22% |
| Q3 2016 | 17.75% |
| Q2 2016 | -13.61% |
| Q1 2016 | 16.22% |
| Q4 2015 | 20.72% |